Earnings Highlights
EPS Actual
$-0.127
EPS Estimate
$-0.1212
Revenue Actual
$None
Revenue Estimate
***
We focus on stock market intelligence, including earnings analysis, valuation trends, and sector performance tracking.
Nexalin Technology (NXL) recently released its publicly available the previous quarter earnings results, marking the latest financial update for the pre-revenue medical technology firm focused on non-invasive neurostimulation therapies for mood and neurological disorders. The company reported adjusted earnings per share (EPS) of -0.127 for the quarter, with no revenue figures included in the earnings release, consistent with the firm’s current phase of clinical development and pre-commercial ope